Ligong Nie

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Journal: Cancer communications (London, England)

Published: January 08, 2026

Successful Treatment With Neoadjuvant Chemo-Immunotherapy for Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Patient Report and Literature Review.

Successful Treatment With Neoadjuvant Chemo-Immunotherapy for Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Patient Report and Literature Review.

Journal: International journal of surgical pathology

Published: December 09, 2025

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: April 24, 2025

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Journal: Lancet (London, England)

Published: September 14, 2024

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Journal: Cancer medicine

Published: March 17, 2024

The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.

The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.

Journal: Scientific reports

Published: February 26, 2024

Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study.

Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study.

Journal: Health science reports

Published: October 27, 2023

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.

Journal: Thoracic cancer

Published: February 03, 2022

Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study.

Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study.

Journal: Thoracic cancer

Published: December 27, 2021

Diffuse large B-cell lymphoma presenting as reversible intrapulmonary arteriovenous shunts with hypoxia, fever and progressive jaundice: a case report and literature review.

Diffuse large B-cell lymphoma presenting as reversible intrapulmonary arteriovenous shunts with hypoxia, fever and progressive jaundice: a case report and literature review.

Journal: BMC pulmonary medicine

Published: September 16, 2021

Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.

Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.

Journal: Thoracic cancer

Published: July 14, 2021

Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.

Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.

Journal: Chest

Published: July 13, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026